Sign in
GYRE Stock Price, Chart, Stats & News
Gyre Therapeutics, Inc.
Save
610.09M
Market cap
89.86x
Current P/E
78.13x
Forward P/E
GYRE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 95.35% |
Operating margin | 9.85% |
Pretax margin | 12.38% |
Net margin | 4.31% |
Effective tax rate | 31.56% |
ROA | 3.03% |
ROE | 5.46% |
D/E | 0.01x |
Interest coverage ratio | – |
GYRE valuation
P/E | 89.86x |
P/S | 5.31x |
P/B | 5.83x |
P/CF | 611.92x |
P/FCF | -675.15x |
P/OCF | 611.92x |
PEG | 0.81x |
EV multiple | 44.53x |
About
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease.
Similar securities
Based on sector and market capitalization
Report issue